DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Daunoxome (Daunorubicin Citrate) - Drug Interactions, Contraindications, Overdosage, etc

 
 



DRUG INTERACTIONS

Drug Interactions

In the patient population studied, DaunoXome has been administered to patients receiving a variety of concomitant medications (e.g., antiretroviral agents, antiviral agents, anti-infective agents). Although interactions of DaunoXome (daunorubicin citrate liposome injection) with other drugs have not been observed, no systematic studies of interactions have been conducted.

OVERDOSAGE

The symptoms of acute overdosage are increased severities of the observed dose-limiting toxicities of therapeutic doses of DaunoXome, myelosuppression (especially granulocytopenia), fatigue, and nausea and vomiting.

CONTRAINDICATIONS

Therapy with DaunoXome is contraindicated in patients who have experienced a serious hypersensitivity reaction to previous doses of DaunoXome or to any of its constituents.

REFERENCES

  1. ONS Clinical Practice Committee. Cancer Chemotherapy Guidelines and Recommendations for Practice. Pittsburg, Pa: Oncology Nursing Society; 1999:32–41.
  2. Recommendations for the Safe Handling of Parenteral Antineoplastic Drugs. Washington, DC: Division of Safety, Clinical Center Pharmacy Department and Cancer Nursing Services, National Institutes of Health; 1992. US Dept of Health and Human Services, Public Health Service Publication NIH 92-2621.
  3. AMA Council on Scientific Affairs. Guidelines for Handling Parenteral Antineoplastics. JAMA. 1985;253:1590–1591.
  4. National Study Commission on Cytotoxic Exposure - Recommendations for Handling Cytotoxic Agents. 1987. Available from Louis P. Jeffrey, Sc.D., Chairman, National Study Commission on Cytotoxic Exposure. Massachusetts College of Pharmacy and Allied Health Sciences, 179 Longwood Avenue, Boston, MA 02115.
  5. Clinical Oncological Society of Australia. Guidelines and Recommendations for Safe Handling of Antineoplastic Agents. Med J Australia. 1983;1:426–428.
  6. Jones RB, Frank R, Mass T. Safe Handling of Chemotherapeutic Agents: A Report from the Mount Sinai Medical Center. CA-A Cancer J for Clin. 1983;33:258–263.
  7. American Society of Hospital Pharmacists. ASHP Technical Assistance Bulletin on Handling Cytotoxic and Hazardous Drugs. Am J Hosp Pharm. 1990;47:1033–1049.
  8. Controlling Occupational Exposure to Hazardous Drugs. (OSHA Work-Practice Guidelines). Am J Health-Syst Pharm. 1996;53:1669–1685.

Manufactured for
Galen US Inc.
25 Fretz Road
Souderton
PA 18964

For medical information about DaunoXome (daw-nuh-zome), call 1-800-280-5708

DaunoXome is a registered trademark of Galen Limited.


Copyright 2011, Galen Limited.

All rights reserved.

Rev. December 2011

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017